Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julien Calderaro

Showing results (151-160 of 181) with videos related to

Pageof 19
Sort By:
Gastroenterology|May 8, 2019
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of ResponseStefano Caruso, Anna-Line Calatayud, Jill Pilet, et al.
Cancer Research Communications|December 21, 2023
Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 ExpressionMarta Ligero, Garazi Serna, Omar S M El Nahhas, et al.
Cancer Cell|April 17, 2014
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformationCamilla Pilati, Eric Letouzé, Jean-Charles Nault, et al.
Nature Communications|December 12, 2018
Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stressQuentin Bayard, Léa Meunier, Camille Peneau, et al.
The Lancet Regional Health. Europe|March 17, 2025
Mapping the landscape of biliary tract cancer in Europe: challenges and controversiesLorenza Rimassa, Shahid Khan, Bas Groot Koerkamp, et al.
JHEP Reports : Innovation in Hepatology|May 1, 2026
Vessels Encapsulating Tumor Clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumabAlexandre Sayadi, Claudia Campani, Astrid Laurent-Bellue, et al.
Hepatology (Baltimore, Md.)|January 26, 2026
Stroma-driven inter- and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluationAnna Saborowski, Simon Peters, Jinbo Zhao, et al.
Hepatology (Baltimore, Md.)|December 28, 2017
Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevanceMarianne Ziol, Nicolas Poté, Giuliana Amaddeo, et al.
Liver Cancer|September 26, 2022
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic HepatocholangiocarcinomaElia Gigante, Christian Hobeika, Brigitte Le Bail, et al.
Nature Communications|May 19, 2026
Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypesLong Pan, Théo Z Hirsch, Jing Fang, et al.
Pageof 19

Showing results (151-160 of 181) with videos related to

Sort By:
Pageof 19
Gastroenterology|May 8, 2019
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of ResponseStefano Caruso, Anna-Line Calatayud, Jill Pilet, et al.
Cancer Research Communications|December 21, 2023
Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 ExpressionMarta Ligero, Garazi Serna, Omar S M El Nahhas, et al.
Cancer Cell|April 17, 2014
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformationCamilla Pilati, Eric Letouzé, Jean-Charles Nault, et al.
Nature Communications|December 12, 2018
Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stressQuentin Bayard, Léa Meunier, Camille Peneau, et al.
The Lancet Regional Health. Europe|March 17, 2025
Mapping the landscape of biliary tract cancer in Europe: challenges and controversiesLorenza Rimassa, Shahid Khan, Bas Groot Koerkamp, et al.
JHEP Reports : Innovation in Hepatology|May 1, 2026
Vessels Encapsulating Tumor Clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumabAlexandre Sayadi, Claudia Campani, Astrid Laurent-Bellue, et al.
Hepatology (Baltimore, Md.)|January 26, 2026
Stroma-driven inter- and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluationAnna Saborowski, Simon Peters, Jinbo Zhao, et al.
Hepatology (Baltimore, Md.)|December 28, 2017
Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevanceMarianne Ziol, Nicolas Poté, Giuliana Amaddeo, et al.
Liver Cancer|September 26, 2022
Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic HepatocholangiocarcinomaElia Gigante, Christian Hobeika, Brigitte Le Bail, et al.
Nature Communications|May 19, 2026
Integrated genomic analyses identify oncogenic pathway interplay in hepatocarcinogenesis defining specific molecular subtypesLong Pan, Théo Z Hirsch, Jing Fang, et al.
Pageof 19